Charles Schwab’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.1M | Buy |
2,589,202
+310,801
| +14% | +$1.57M | ﹤0.01% | 1886 |
|
|
2025
Q1 | $12.1M | Buy |
2,278,401
+4,398
| +0.2% | +$23.3K | ﹤0.01% | 1863 |
|
|
2024
Q4 | $15.4M | Buy |
2,274,003
+333,323
| +17% | +$2.25M | ﹤0.01% | 1829 |
|
|
2024
Q3 | $12.8M | Buy |
1,940,680
+288,926
| +17% | +$1.9M | ﹤0.01% | 1915 |
|
|
2024
Q2 | $12.4M | Buy |
1,651,754
+438,742
| +36% | +$3.29M | ﹤0.01% | 1934 |
|
|
2024
Q1 | $12.1M | Buy |
1,213,012
+22,130
| +2% | +$221K | ﹤0.01% | 1899 |
|
|
2023
Q4 | $11.7M | Buy |
1,190,882
+32,916
| +3% | +$325K | ﹤0.01% | 1900 |
|
|
2023
Q3 | $8.86M | Buy |
1,157,966
+157,189
| +16% | +$1.2M | ﹤0.01% | 1978 |
|
|
2023
Q2 | $7.48M | Buy |
1,000,777
+16,838
| +2% | +$126K | ﹤0.01% | 2049 |
|
|
2023
Q1 | $6.56M | Sell |
983,939
-742
| -0.1% | -$4.95K | ﹤0.01% | 2074 |
|
|
2022
Q4 | $7.59M | Buy |
984,681
+80,177
| +9% | +$618K | ﹤0.01% | 2002 |
|
|
2022
Q3 | $9.62M | Buy |
904,504
+476,162
| +111% | +$5.07M | ﹤0.01% | 1857 |
|
|
2022
Q2 | $3.49M | Buy |
428,342
+55,178
| +15% | +$449K | ﹤0.01% | 2350 |
|
|
2022
Q1 | $2.67M | Sell |
373,164
-4,075
| -1% | -$29.2K | ﹤0.01% | 2548 |
|
|
2021
Q4 | $6.46M | Buy |
377,239
+194,467
| +106% | +$3.33M | ﹤0.01% | 2223 |
|
|
2021
Q3 | $4.21M | Buy |
182,772
+17,891
| +11% | +$412K | ﹤0.01% | 2455 |
|
|
2021
Q2 | $6.02M | Buy |
+164,881
| New | +$6.02M | ﹤0.01% | 2256 |
|